These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15343508)

  • 1. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
    Brunt EM; Neuschwander-Tetri BA; Oliver D; Wehmeier KR; Bacon BR
    Hum Pathol; 2004 Sep; 35(9):1070-82. PubMed ID: 15343508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
    Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Sponseller CA; Hampton K; Bacon BR
    J Hepatol; 2003 Apr; 38(4):434-40. PubMed ID: 12663234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
    Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
    Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
    J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
    Ratziu V; Charlotte F; Bernhardt C; Giral P; Halbron M; Lenaour G; Hartmann-Heurtier A; Bruckert E; Poynard T;
    Hepatology; 2010 Feb; 51(2):445-53. PubMed ID: 19877169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic steatosis in obese Chinese children.
    Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
    Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
    Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.
    Setji TL; Holland ND; Sanders LL; Pereira KC; Diehl AM; Brown AJ
    J Clin Endocrinol Metab; 2006 May; 91(5):1741-7. PubMed ID: 16492691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.
    Lomonaco R; Ortiz-Lopez C; Orsak B; Finch J; Webb A; Bril F; Louden C; Tio F; Cusi K
    Hepatology; 2011 Sep; 54(3):837-45. PubMed ID: 21674556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.
    Wang CH; Leung CH; Liu SC; Chung CH
    J Formos Med Assoc; 2006 Sep; 105(9):743-52. PubMed ID: 16959622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
    Caldwell SH; Hespenheide EE; Redick JA; Iezzoni JC; Battle EH; Sheppard BL
    Am J Gastroenterol; 2001 Feb; 96(2):519-25. PubMed ID: 11232700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.